TCW Group Inc. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 11.6% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,057,389 shares of the biopharmaceutical company’s stock after selling 268,717 shares during the quarter. Gilead Sciences accounts for approximately 1.3% of TCW Group Inc.’s holdings, making the stock its 22nd biggest holding. TCW Group Inc. owned approximately 0.16% of Gilead Sciences worth $158,851,000 at the end of the most recent quarter.
Other institutional investors have also made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Gilead Sciences by 11.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after purchasing an additional 3,221,439 shares during the last quarter. Northern Trust Corp grew its holdings in Gilead Sciences by 2.0% during the 2nd quarter. Northern Trust Corp now owns 16,823,192 shares of the biopharmaceutical company’s stock worth $1,191,754,000 after acquiring an additional 325,246 shares during the last quarter. Sanders Capital LLC grew its holdings in Gilead Sciences by 7.0% during the 2nd quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after acquiring an additional 696,200 shares during the last quarter. Boston Partners grew its holdings in Gilead Sciences by 3.1% during the 2nd quarter. Boston Partners now owns 8,290,507 shares of the biopharmaceutical company’s stock worth $587,300,000 after acquiring an additional 245,805 shares during the last quarter. Finally, OppenheimerFunds Inc. grew its holdings in Gilead Sciences by 0.3% during the 2nd quarter. OppenheimerFunds Inc. now owns 7,038,387 shares of the biopharmaceutical company’s stock worth $498,599,000 after acquiring an additional 22,916 shares during the last quarter. 78.23% of the stock is currently owned by hedge funds and other institutional investors.
Gilead Sciences stock opened at $72.04 on Wednesday. The company has a debt-to-equity ratio of 1.36, a quick ratio of 3.39 and a current ratio of 3.47. Gilead Sciences, Inc. has a 1 year low of $64.27 and a 1 year high of $89.54. The stock has a market cap of $90.41 billion, a price-to-earnings ratio of 8.42, a price-to-earnings-growth ratio of -3.58 and a beta of 1.01.
The firm also recently announced a quarterly dividend, which will be paid on Friday, December 28th. Shareholders of record on Friday, December 14th will be given a dividend of $0.57 per share. The ex-dividend date is Thursday, December 13th. This represents a $2.28 dividend on an annualized basis and a yield of 3.16%. Gilead Sciences’s payout ratio is presently 26.64%.
In other Gilead Sciences news, Director John C. Martin sold 50,000 shares of the company’s stock in a transaction dated Monday, October 1st. The shares were sold at an average price of $78.04, for a total transaction of $3,902,000.00. Following the transaction, the director now directly owns 3,067,762 shares in the company, valued at approximately $239,408,146.48. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.16% of the company’s stock.
GILD has been the topic of a number of research analyst reports. BidaskClub raised shares of Gilead Sciences from a “hold” rating to a “buy” rating in a report on Thursday, October 11th. Mizuho reissued a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a report on Friday, August 10th. Piper Jaffray Companies set a $85.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Wednesday, September 12th. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Friday, September 28th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a report on Wednesday, July 18th. Thirteen equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $87.84.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.
Read More: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.